I'm LongbridgeAI, I can summarize articles.Ocumetics Technology Corp. has closed the first tranche of its brokered private placement, raising approximately $788,380, alongside a concurrent non-brokered placement of $235,450, totaling about $1,023,830. The offerings, led by Centurion One Capital, involved the sale of 1,706,383 units at $0.60 each, with proceeds aimed at funding clinical trials and R&D. The company also paid $143,336.17 in fees and issued additional warrants. The placements are considered related party transactions and were approved by the board.
(TheNewswire)
Calgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the“Corporation”) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it hasclosed the first tranche of its previouslyannounced best efforts brokered privateplacement of units of the Company (the “Units”) foraggregate gross proceeds of approximately $788,380 (the “BrokeredOffering”). The Companyis also pleased to announce the closing of a concurrent non-brokeredprivate placement of Units for additional gross proceeds ofapproximately $235,450 (the “Non-Brokered Offering” and together with the Brokered Offering, the“Offerings”).
The Offerings were led by Centurion One Capital Corp.as lead agent and sole bookrunner (the “Lead Agent”) inrespect of the Brokered Offering and fiscal advisor in respect of theNon-Brokered Offering. Tingle Merrett LLP acted as counsel to theCompany, and Cassels Brock & Blackwell LLP acted as counsel to theLead Agent in connection with the Offerings.
A total of 1,706,383 Units weresold under the Offerings at a price of $0.60 per Unit (the“Issue Price”) for aggregate gross proceeds of approximately$1,023,830. Each Unit consists of one commonshare in the capital of the Company (a “Common Share”) andone Common Share purchase warrant (a “Warrant”). EachWarrant entitles the holder to purchase one additional Common Share (a“Warrant Share”) at a price of $0.75 until December30, 2028.
The gross proceeds of the Offering are expected to beused to fund the Corporation’s first-in-human clinical trials, forongoing research and development and for general corporate purposes. Although the Corporation intends to use the proceeds of the offeringas described above, the actual allocation of proceeds may vary fromthe uses set out above, depending upon future operations, events oropportunities.
In connection with the
Offerings, the Company paid an aggregate of $143,336.17 in commissions, fees and advisory fees, $61,429.79 of which were
paid through the issuance of an aggregate of 102,382 Units, and issued
an aggregate of 136,510 Common Share purchase warrants with each
warrant entitling the holder thereof to acquire one Unit at the Issue
Price until December 30, 2028. The Lead Agent intends to close the
rest of the Offerings in one or more subsequent tranches.
The Units offered for sale under the Offerings were
offered by way of private placement (i) pursuant to the listed issuer
financing exemption (the “Listed Issuer Financing Exemption”) under
section 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order
45-935 – Exemptions from
Certain Conditions of the Listed Issuer Financing
Exemption, and (ii) and in
the United States pursuant to available exemptions from the
registration requirements of the United States Securities Act of 1933,
as amended (the “U.S.
Securities Act”). The
securities issued under the Listed Issuer Financing Exemption will not
be subject to a statutory hold period pursuant to applicable Canadian
securities laws.
Dean Burns (Chief Executive Officer and President),
Roger Jewett (Chief Financial Officer), Garth Webb (Chief Scientific
Officer), Doyle Stulting (Chief Medical Officer), J. Barton McRoberts
and Michael Edwards, all of whom are directors of the Corporation,
participated in the Private Placement. The Private Placement is
therefore a “Related Party Transaction” under Multilateral
Instrument 61-101 – Protection of Minority Security Holders in
Special Transactions (“MI
61-101”). The Corporation relied upon the
exemptions from the minority shareholder approval and valuation
requirements set out in Sections 5.7(1)(a) and 5.5(a), respectively,
of MI 61-101. The Private Placement was approved unanimously by the
directors of the Corporation by resolution. A material change report
regarding the Private Placement was not filed 21 days before the
completion of the Private Placement as 21 days prior to the completion
of the Private Placement, completion of the
Private Placement was uncertain and therefore did not at that time
constitute a material change.
This news release does not constitute an offer to sell
or a solicitation of an offer to buy any of the securities in the
United States. The securities have not been and will not be registered
under the U.S. Securities Act or any state securities laws and may not
be offered or sold within the United States or to U.S. persons unless
registered under the U.S. Securities Act and applicable state
securities laws or an exemption from such registration is
available.
ABOUT OCUMETICS
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)
(FRA: 2QB0) is a Canadian research and product development company
that is dedicated to developing advanced vision correction solutions
that enhance the quality of life for patients. Through innovative
research and development, Ocumetics aims to transform the field of
ophthalmology with state-of-the-art intraocular lenses and other
vision-enhancing technologies.
Ocumetics is in the preclinical study stage of a
game-changing technology for the ophthalmic industry. Ocumetics has
developed an intraocular lens that fits within the natural lens
compartment of the eye potentially to eliminate the need for
corrective lenses. It is designed to allow the eye’s natural muscle
activity to shift focus from distance to near, providing clear vision
at all distances without the help of glasses or contact lenses.
Additional information is available at
www.ocumetics.com and www.sedarplus.ca.
For further information, please contact:
Mr. Dean Burns
President and CEO
Tel: 817-874-7564
About Centurion One Capital
Centurion One Capital's mission is to ignite the
world's most visionary entrepreneurs to conquer the greatest
challenges of tomorrow, fueling their ambitions with transformative
capital, unparalleled expertise, and a global network of influential
connections. Every interaction is guided by our core values of
respect, integrity, commitment, excellence in execution, and
uncompromising performance. We make principal investments, drawing on
the time-honored principles of merchant banking, where aligned
incentives forge enduring partnerships. Centurion One Capital: A
superior approach to investment banking.
Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS:
This news release contains certain “forward-looking
information” within the meaning of applicable Canadian securities
legislation. Generally, forward-looking
information can be identified by the use of forward-looking
terminology such as “plans”, “expects” or “does not
expect”, “is expected”, “budget”, “scheduled”,
“estimates”, “forecasts”, “intends”, “anticipates” or
“does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will be
taken”, “occur” or “be achieved”. Forward-looking statements include, but are not limited to,
statements with respect to the completion of the
Offering and the anticipated Closing Date
thereof; the expected receipt of regulatory and Exchange approvals
relating to the Offering; the expected proceeds
of the Offering and the anticipated use thereof; and any other
activities, events or developments that the companies expect or
anticipate will or may occur in the future.
Forward-looking statements are necessarily based upon a
number of estimates and assumptions that, while considered reasonable,
are subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to differ
materially from those expressed or implied by such forward-looking
statements. Such factors include but are not limited to: operational
matters, historical trends, current conditions and expected future
developments, access to financing as well as other considerations that
are believed to be appropriate in the circumstances. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements. The Corporation
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
NOT FOR
DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION
IN THE UNITED STATES
Copyright (c) 2026 TheNewswire - All rights reserved.